The specific cell lines and their respective KRAS mutations responsive to the cytolytic effects of 4SP65 included A549 and H460 NSCLC cell lines with KRAS G12S and Q61H mutations, respectively, MDA-MB-231 breast cancer cells with a KRAS G13D mutation plus a highly expressed TP53 R280K mutation, TOV21G ovarian cancer cells with a KRAS G13C mutation, and PANC1 pancreatic cancer cells with a KRAS G12D mutation plus a TP53 818G>A mutation (70–73). This evidence concerns the gene KRAS and ovarian carcinoma.